Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review
Journal Title
Future Oncology
Publication Type
Online publication before print
Abstract
Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.; [Box: see text].; eng
Keywords
Rcc; Sabr; Sbrt; cytoreduction; immunotherapy; metastasis-directed therapy; oligometastatic; oligoprogressive; renal cell carcinoma
Department(s)
Radiation Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-26 03:27:20
Last Modified: 2024-09-26 03:32:37

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙